Dark

Check out our API

BNOEF
BIONOMIC LTD PAR ORD
stock OTC

Inactive

Sep 18, 2023

0.0060USD-14.894%(-0.0011)72,739

Pre-market

0.00USD-100.000%(-0.01)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 5, 2022

05:59PM EST Bionomics Limited Announces Full Exercise of Underwriters' Option to Purchase PR Newswire

Dec 16, 2021

06:03AM EST Bionomics Prices IPO Of 1.622 Mln ADSs At US$12.35/ADSs RTTNews

06:01AM EST Bionomics Limited Announces Pricing of Initial Public Offering in the United PR Newswire

Dec 1, 2021

06:31AM EST Bionomics: FDA Grants Fast Track Designation To BNC210 For Acute Treatment Of Social Anxiety Disorder RTTNews

06:01AM EST U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute PR Newswire

Nov 23, 2021

06:39AM EST Bionomics Files Registration Statement For Proposed IPO In U.S. RTTNews

06:37AM EST Bionomics Files Registration Statement for Proposed Initial Public Offering in PR Newswire

Nov 1, 2021

06:03AM EDT Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In A Phase 2 Social Anxiety Disorder PREVAIL Study RTTNews

06:01AM EDT Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 PR Newswire

Sep 20, 2021

06:02AM EDT Bionomics Says Prepares BNC210 For Start Of Phase 2 Acute Treatment Of Social Anxiety Disorder Trial RTTNews

06:00AM EDT Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social PR Newswire

Aug 2, 2021

06:06AM EDT Bionomics Announces Plans To Conduct U.S. IPO Of ADSs And A Concurrent Listing Of ADSs On Nasdaq RTTNews

06:00AM EDT Bionomics Announces Plans to Conduct U.S. Initial Public Offering PR Newswire

Jul 6, 2021

06:04AM EDT Bionomics Initiates Phase 2b ATTUNE Study Of BNC210 In Post-Traumatic Stress Disorder RTTNews

06:01AM EDT Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD PR Newswire

May 10, 2021

06:01AM EDT Bionomics BNC210 Expansion into Social Anxiety Disorder PR Newswire

Apr 9, 2021

06:09AM EDT Bionomics Completes 1 For 6 Pro Rata Non-renounceable Entitlement Offer RTTNews

06:00AM EDT Bionomics Successfully Completes A$22.9 million Equity Raise PR Newswire

Feb 22, 2021

06:05AM EST Bionomics Announces Positive Pharmacokinetic Results From 7-day Dosing Study RTTNews

06:01AM EST Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure PR Newswire

Feb 17, 2021

06:00AM EST Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA PR Newswire

Feb 10, 2021

06:01AM EST $16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial PR Newswire

Share